Serina Therapeutics (SER) Preferred Stock Liabilities (2023)
Serina Therapeutics (SER) posted Preferred Stock Liabilities of $36.4 million for Q4 2023, up 345.59% sequentially from -$14.8 million in Q3 2023.
Serina Therapeutics (SER) Preferred Stock Liabilities (2023) Analysis & Trends
Serina Therapeutics has reported Preferred Stock Liabilities for 1 years, with the latest figure at $36.4 million in Q4 2023.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $36.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $36.4 million (changed N/A YoY) and the FY2023 annual result came in at $36.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities advanced to $36.4 million in Q4 2023 per SER's latest filing, from -$14.8 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $36.4 million in Q4 2023 and troughed at -$14.8 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Serina Therapeutics | 46.70 Mn | 23.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 36.40 Mn |
| Sep 30, 2023 | -14.82 Mn |